{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:56Z","timestamp":1792197296305,"version":"4.4.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006298","name":"S\u00e4chsische Aufbaubank","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ccell.2020.03.006","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T10:33:08Z","timestamp":1586773988000},"page":"530-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":443,"title":["Response and Resistance to BCR-ABL1-Targeted Therapies"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-2143","authenticated-orcid":false,"given":"Theodore P.","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2020.03.006_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","article-title":"A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ccell.2020.03.006_bib2","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"PI3K\/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","author":"Airiau","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ccell.2020.03.006_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74\u2013ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2020.03.006_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission","volume":"8","author":"Bocchia","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2020.03.006_bib7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib8","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib9","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the molecular network of the drug target Bcr-Abl","volume":"106","author":"Brehme","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ccell.2020.03.006_bib10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib11","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.03.006_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib13","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2020.03.006_bib14","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib15","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib16","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/geno.1995.1008","article-title":"Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation","volume":"27","author":"Chissoe","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.ccell.2020.03.006_bib142","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ccell.2020.03.006_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","article-title":"In\u00a0vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor","volume":"91","author":"le Coutre","year":"1999","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ccell.2020.03.006_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ccell.2020.03.006_bib21","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1080\/10428194.2017.1421755","article-title":"Monitoring of leukemia stem cells in chronic myeloid leukemia patients","volume":"59","author":"Cui","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ccell.2020.03.006_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V99.4.1388","article-title":"Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2","volume":"99","author":"Dorsey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib143","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic Myelogenous Leukemia: Biology and Therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","article-title":"High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients\u2013\u2013systematic review and meta-analysis","volume":"86","author":"Gafter-Gvili","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ccell.2020.03.006_bib34","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib35","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Gioia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib144","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1084\/jem.20141661","article-title":"A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression","volume":"212","author":"Giotopoulos","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib36","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib37","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.03.006_bib39","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1182\/blood-2005-08-3399","article-title":"A common phosphotyrosine signature for the Bcr-Abl kinase","volume":"107","author":"Goss","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, Bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ejh.12743","article-title":"Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence","volume":"97","author":"Gunnarsson","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ccell.2020.03.006_bib43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ccell.2020.03.006_bib45","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib46","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","article-title":"The coiled-coil domain and Tyr177 of Bcr are required to induce a murine chronic myelogenous leukemia-like disease by Bcr\/abl","volume":"99","author":"He","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib47","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib48","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib49","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib50","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/sj.onc.1205452","article-title":"BCR\/ABL P190 transgenic mice develop leukemia in the absence of Crkl","volume":"21","author":"Hemmeryckx","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2020.03.006_bib51","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib52","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib53","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"10.1016\/j.ccell.2020.03.006_bib146","first-page":"S5","article-title":"Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry","volume":"17","author":"Horowitz","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ccell.2020.03.006_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib55","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib56","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib147","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1986.4.7.1079","article-title":"High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis","volume":"4","author":"Iacoboni","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib57","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib58","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ccell.2020.03.006_bib59","doi-asserted-by":"crossref","first-page":"e55717","DOI":"10.1371\/journal.pone.0055717","article-title":"Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era","volume":"8","author":"Iqbal","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2020.03.006_bib60","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.03.006_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ccell.2020.03.006_bib62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2020.03.006_bib63","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FTD.0b013e318292b931","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring","volume":"35","author":"Josephs","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ccell.2020.03.006_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib65","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib66","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib67","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In\u00a0vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib68","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cncr.24155","article-title":"Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations","volume":"115","author":"Khoury","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2020.03.006_bib148","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim","year":"2017","journal-title":"Leukemia Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib69","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib71","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/2472555217695080","article-title":"A high-throughput method for measuring drug residence time using the transcreener ADP assay","volume":"22","author":"Kumar","year":"2017","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ccell.2020.03.006_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8735","article-title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia","volume":"10","author":"Lai","year":"2018","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib73","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2020.03.006_bib74","doi-asserted-by":"crossref","first-page":"e29828","DOI":"10.1371\/journal.pone.0029828","article-title":"Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain","volume":"7","author":"Levinson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2020.03.006_bib75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib76","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1200\/jco.2014.32.15_suppl.7023","article-title":"EPIC: a phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML","volume":"32","author":"Lipton","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib77","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib78","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.03.006_bib79","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib80","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib81","doi-asserted-by":"crossref","first-page":"e18542","DOI":"10.1200\/JCO.2016.34.15_suppl.e18542","article-title":"Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP)","volume":"34","author":"Maiti","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib82","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib83","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib84","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: a review of efficacy and safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ccell.2020.03.006_bib85","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V96.2.664","article-title":"The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr\/Abl tyrosine kinase","volume":"96","author":"Million","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib149","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib86","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib87","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"142","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.03.006_bib88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib89","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-12-3904","article-title":"Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis","volume":"73","author":"O\u2019Hare","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib90","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib91","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Packer","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib92","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib93","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib94","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib95","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2020.03.006_bib96","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib97","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib98","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0002-9343(77)90199-1","article-title":"Blast crisis of chronic granulocytic leukemia: morphologic variants and therapeutic implications","volume":"63","author":"Rosenthal","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib99","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib100","first-page":"1","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib102","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.03.006_bib103","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.03.006_bib104","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Samanta","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib106","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib107","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib108","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.03.006_bib109","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib110","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1158\/1078-0432.CCR-18-0167","article-title":"Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias","volume":"24","author":"Schmitt","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib111","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib112","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.03.006_bib113","doi-asserted-by":"crossref","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","article-title":"Revised estimates for the number of human and bacteria cells in the body","volume":"14","author":"Sender","year":"2016","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ccell.2020.03.006_bib114","doi-asserted-by":"crossref","first-page":"23255","DOI":"10.1074\/jbc.271.38.23255","article-title":"The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene","volume":"271","author":"Senechal","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2020.03.006_bib115","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.1158\/0008-5472.CAN-10-0607","article-title":"A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors","volume":"70","author":"Seo","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib116","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.03.006_bib117","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ccell.2020.03.006_bib118","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.03.006_bib119","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.03.006_bib121","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","author":"Snead","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib122","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib123","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.leukres.2008.10.015","article-title":"Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase","volume":"33","author":"Stagno","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib124","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1055-9965.EPI-09-0028","article-title":"Obesity, weight gain, and risk of chronic myeloid leukemia","volume":"18","author":"Strom","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ccell.2020.03.006_bib125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ccell.2020.03.006_bib126","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.03.006_bib127","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib128","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","article-title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations","volume":"123","author":"Traer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib129","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib130","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib131","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2020.03.006_bib132","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib133","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","article-title":"Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells","volume":"7","author":"Weisberg","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2020.03.006_bib134","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jmb.2016.12.019","article-title":"Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance","volume":"429","author":"Willemsen-Seegers","year":"2017","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ccell.2020.03.006_bib135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.03.006_bib136","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","article-title":"Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation","volume":"20","author":"Xie","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2020.03.006_bib137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.03.006_bib138","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.03.006_bib139","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of \u03b2-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in\u00a0vitro and in\u00a0vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2020.03.006_bib140","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"Zhou","year":"2008","journal-title":"J.\u00a0Exp. Med."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082030146X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082030146X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:05:11Z","timestamp":1761523511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561082030146X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S153561082030146X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response and Resistance to BCR-ABL1-Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}